Advanced Search
eLetter submission guidelines
More information about text formats
A lot of NHS primary care time is spent monitoring conditions that, in themselves, may not add value to the patient and could perhaps be handed back to the person to do themselves. At the same time, nobody monitors the million or so who obtain prescription-only medicines for GLP-1 agonists (and others) with no checks or balances (and none of the regulators appears to care or intervene). GPs do not prescribe them, as the design of NHS pathways and protocols is there to stop us. But if the consumer or patient perceives a benefit, and much evidence suggests this is of an order of magnitude greater in terms of NNT compared to most drugs we prescribe, should primary care not be monitoring and advising this group? Or will these be added to ADHD drugs, children's melatonin, etc., where the backlash from primary care is that it is 'not our job' (like spirometry ear syringing, etc.)
Thank you for recommending British Journal of General Practice.
NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
British Journal of General Practice
